IBD Relief


Relief from irritable bowel discomfort

  • Provides key enzymes for improved digestion and nutrient absorption
  • Promotes healthy intestinal flora
  • Clinically researched herbs and nutrients to control gastrointestinal inflammation
Gluten Free
Vegan Society

$46.19 or subscribe and save 20%

Out of stock

Inflammatory bowel disorders (IBD) are characterized by cycles of chronic relapses and remissions, chronic inflammation of the intestinal mucosa and an abnormal gut micro-flora. Sufferers tend to be afflicted by symptoms of poor digestion including gas, bloating and abdominal pain. These disorders can involve food sensitivities to common allergens such as gluten, which is found in certain grains, and casein which is found in dairy products. Celiac Disease, a type of severe gluten intolerance, is believed to affect 1 in 200 people in the modernized world.  It causes an immune response to gluten which leads to intestinal inflammation and results in a decreased ability of the body to absorb nutrients.

IBD Relief includes specialized digestive enzymes that help to prevent the intestinal inflammation related to food intolerances and chronic intestinal disorders. These include AN-peptidases which are a source of DPP-IV, which break down gluten and other problematic proteins. Anti-inflammatory and stress-relieving botanicals Boswellia serrata, ashwagandha, and ginger are also included in the formula, as well as vitamin D3 which is important for immune system regulation. The probiotic yeast Saccharomyces boulardii also helps to reduce inflammation in the gut and protect the bowel from pathogens by promoting healthy intestinal flora.

AOR Advantage

AOR’s IBD Relief provides an innovative and effective combination of ingredients to help those with food sensitivities and intestinal inflammation to manage the symptoms and prevent exacerbation of the condition.Those who have inflammatory bowel disorders such as Crohn’s, Celiac Disease or colitis will benefit from taking IBD Relief.




IBD Relief is traditionally used in Herbal medicine to help relieve digestive upset/ disturbances including lack of appetite, nausea, digestive spasms, indigestion, dyspepsia and flatulent colic. It contains digestive enzymes that help digest proteins as well as a probiotic that forms part of a natural healthy gut flora.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sulphites, mustard, dairy, eggs, shellfish or any animal byproduct.

Adult Dosage

Take four capsules daily or two capsules twice daily with meals of your choice, or as directed by a qualified health care practitioner.


Do not use if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment), or if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you have gastrointestinal lesions/ulcers, are taking anticoagulant agents, anti-inflammatory agents or other enzyme products, are having surgery, or if you have nausea, fever, vomiting, bloody diarrhea or severe abdominal pain. Consult a health care practitioner for prolonged use. Discontinue use and consult a health care practitioner if symptoms (e.g. digestive upset, diarrhea) occur, worsen, or persist beyond three days. Hypersensitivity/allergy has been known to occur in which case discontinue use. Consumption with alcohol, other drugs, or natural health products with sedative properties is not recommended. This product contains corn; do not use if you have such allergy.

Main Applications
  • Digestion
  • Celiac disease
  • Immunity

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: Four Capsules
ANPEP™ [protease enzyme from A. niger & A. flavus var. oryzae]
13.64 mg/1,900 HUT*
Ginger (Zingiber officinale)
300 mg
Saccharomyces boulardii
1.33 x 1010 CFU
Boswellia serrata (40% boswellic acids)
600 mg
Vitamin D3 (vegan)
25 mcg/1000 IU
Ashwagandha (Withania somnifera)
100 mg

*FCC-approved units
†Colony-forming units

Non-medicinal Ingredients: Microcrystalline cellulose, potato starch, maltodextrin, tapioca and potato dextrin, sodium stearyl fumarate and sodium benzoate.

Capsule: hypromellose.

Enzymes in Celiac Disease
This preliminary study published in 2009 offers a proof of concept relating to the gluten detoxification properties of two food-grade enzymes, aspergillopepsin (ASP) from Aspergillus niger and dipeptidyl peptidase IV (DPPIV) from Aspergillus oryzae. The study evaluated how efficiently these enzymes are able to hydrolyze gluten. ASP markedly enhanced gluten digestion relative to pepsin and cleaved recombinant a2-gliadin at multiple sites in a non-specific manner, further supplementation of ASP with DPPIV enabled detoxification of moderate amounts of gluten in the presence of excess casein. This makes it an ideal option for the management of gluten and casein sensitivities.

Ehren J, Morón B, Martin E, Bethune MT, Gray GM, Khosla C. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One. 2009;4(7):e6313. Published 2009 Jul 21. doi:10.1371/journal.pone.0006313

Vitamin D and IBD
This multicenter European study published in 2018 followed 238 patients with newly diagnosed IBD (UC and Crohn’s) and assessed the relationship with serum vitamin D levels. In this observational study, the serum vitamin D levels were assessed; and deficiency was characterized by less than 50nmol/l, insufficient if between 50 and 75nmol/l and normal if more than or equal to 75 nmol/l. Demographic information relating to severity, phenotype, quality of life (QoL), and treatment received were all assessed. Reviewers found that low vitamin D likely predisposes induvial to IBD based on the fact that more than half (58.6%) of the patients were vitamin D deficient and 20.7% had insufficient levels of vitamin D at diagnosis. While this may also indicate the malabsorption that occurs as a result of the pathology of IBD. The mechanisms and preclinical work on Vitamin D indicating that it maintains the epithelial mucosal barrier, preventing intestinal permeability, upregulation of claudins and tight junctions, and immune modulation of Th2 differentiation among other mechanisms of action. The severity of diagnosis is also correlated to vitamin D levels whereby severe cases also had lower vitamin D levels. Smoking was also confirmed to inversely correlate with serum vitamin D. While researches cite insufficient evidence from this study to comment on the opportunity of supplementation, they established a clear relationship with disease progression and management and vitamin D levels at baseline making an important therapeutic distinction.

Chetcuti Zammit S, Ellul P, Girardin G, et al. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. Eur J Gastroenterol Hepatol. 2018;30(11):1297-1303. doi:10.1097/MEG.0000000000001238

Vitamin D and Ulcerative Colitis
This double-blind RCT from 2019 where patients with ulcerative colitis (n=50) were given varying doses of vitamin D at low (1000IU/day) or high (2000IU/day) for 12 weeks. Outcomes included disease progression using the Inflammatory Bowel Disease Questionnaire-9 (IBDQ-9) and the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ.) Further outcomes included: serum 25-hydroxy vitamin D (25-OHD) level, total antioxidant capacity (TAC), and Total Oxidant Status (TOS.) All outcomes were measured at baseline and again after 12 weeks. Results showed a significant increase in 25-OHD in the high dose group over the low dose group and were rationalized by the increased requirements of UC patients who suffer from malabsorption. Further, while there was no change in antioxidant capacity there were benefits in both groups to the quality of life assessments. The authors concluded, “2000 IU/day for 12 weeks could lead to an increase in serum 25-OHD levels, improvement of quality of life, and decrease in the disease activity index in adult patients with active mild to moderate UC.”

Karimi S, Tabataba-Vakili S, Yari Z, et al. The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life, and oxidant/antioxidant status. Nutr J. 2019;18(1):16. Published 2019 Mar 11. doi:10.1186/s12937-019-0441-7

Impact of vitamin D supplementation in IBD, A Review

This 2019 review published in Nutrients is a comprehensive review of the available literature- both clinical and preclinical insights. The authors outline the correlation with low vitamin D levels at diagnosis, challenges for adequate dietary absorption. Another important area reviewed was the impact of supplementation on disease progression and outcomes. While the consensus for RDI in individuals with inflammatory concerns remains quite low there are many promising studies showing the safety and efficacy of high doses for prolonged periods of time. The subjects undergoing corticosteroid treatments for IBD had improved bone density with vitamin D supplementation. Hospitalizations, risks of surgery, as a result of disease progression were correlated with vitamin D status. Anemia and colorectal cancer risks were reduced, and subjects had a better response to TNF-alpha treatment. However, markers of inflammation (CRP) and calprotectin had inconsistent reactions to vitamin D supplementation. While a number of studies showed a decrease relating to vitamin D supplementation some failed to show statistically significant decreases.

Fletcher J, Cooper SC, Ghosh S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients. 2019;11(5):1019. Published 2019 May 7. doi:10.3390/nu11051019

Boswellia and Gut health
This 2015 preclinical study on the anti-inflammatory potential of Boswellia on the gut epithelial barrier provides insight into the benefit of this herb as an adjunctive treatment in IBD. Researchers assessed functional, morphological, and molecular biomarkers of intestinal barrier integrity by inducing inflammatory damage to a Caco-2 cell monolayer (using H2O2 or to INF-γ+TNF-α,) and then treating these with Boswellia gum extract. The extract was able to successfully prevent the disassembly of the epithelial monolayer by TJ proteins which act as cellular scaffolding ZO-1 and occluding. The extract was able to counteract the damage and creating of Reactive Oxygen Species (ROS) caused by H2O2 exposure. This positive correlation of anti-inflammatory and antioxidant activity indicates a benefit for damaged intestinal cells.

Catanzaro D, Rancan S, Orso G, et al. Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. PLoS One. 2015;10(5):e0125375. Published 2015 May 8. doi:10.1371/journal.pone.0125375

Ginger Extract on Ulcerative Colitis
This prospective, randomized, double-blind, placebo-controlled trial included 46 participants with active mild to moderate ulcerative colitis. Participants were randomly assigned to receive either ginger (containing 500 mg dried ginger powder)- four capsules X/day or placebo capsules (maltodextrin powder) for 12 weeks. Outcomes measured included serum total antioxidant capacity (TAC) and malondialdehyde (MDA). Researchers rated disease management and quality of life using the validated IBDQ-9 questionnaire. Results found 2000 mg/day ginger supplementation can “improve disease severity index and oxidative stress” further symptoms such as intestinal gas, bloating and abdominal pain decreased after taking ginger.

Nikkhah-Bodaghi M, Maleki I, Agah S, Hekmatdoost A. Zingiber officinale and oxidative stress in patients with ulcerative colitis: A randomized, placebo-controlled, clinical trial. Complement Ther Med. 2019;43:1-6. doi:10.1016/j.ctim.2018.12.021

Saccharomyces boulardii Potential on IBD
This review published in 2018 assessed four human clinical trials and three reviews ¾ studies were able to demonstrate significant benefits to probiotic supplementation. The studies that found benefit were smaller-scale studies though there were not standardizations between the doses of the Saccharomyces and most studies were in patients with Crohn’s disease and only one in ulcerative colitis. Pre-clinical research studies provide some insight into the mechanisms of action for managements in IBD- “better adherence junctions because of E-cadherin, decreased CD40 and CD80-positive mDC, decreased avb5-signaling pathway and activation of the a2b1-integrin collagen receptor, reduction of proinflammatory mediators as IL-1b, IL-6, TNF-a, iNOS and activation of PPAR-c.” The researchers concluded that an additional long-term study is warranted.

Sivananthan K, Petersen AM. Review of Saccharomyces boulardii as a treatment, 34 patients have IBD. Immunopharmacol Immunotoxicol. 2018;40(6):465-475. doi:10.1080/08923973.2018.1469143

Ashwagandha in Chronic Stress
In this 2012 RCT, 64 subjects (32 in placebo and 32 in the intervention group) with a history of chronic stress were evaluated for 60 days. The intervention group received 300mg BID of a full spectrum ashwagandha extract, compliance was good with only three dropouts reported. Four validated questionnaires were used as a measure of stress and anxiety (GHQ-28, DASS- anxiety insomnia and stress subset, and PSS), and secondary measures included impacts on stress such as serum cortisol. On all metrics, the treatment arm showed statistically significant improvements compared to the placebo. Including a 44% decrease in the PSS scores compared to the 5.5% reduction in the placebo group. Since the relationship with stress and exacerbations with IBD are well-established stress management is an important aspect of overall management.

Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255-262. doi:10.4103/0253-7176.106022